Navigation Links
AEterna Zentaris Sells Quebec City Building for $7.1 million
Date:6/27/2008

All amounts are in U.S. dollars

QUEBEC CITY, June 27 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ;), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced it has completed the sale of its Quebec City property for a purchase price of $7.1 million, payable in cash. AEterna Zentaris also entered into a long-term lease agreement enabling the Company to continue occupying its current space for its Quebec City operations.

Juergen Ernst, Chairman and Interim President and CEO of AEterna Zentaris stated, "We are very pleased to have completed the sale of our Quebec City property. This is in line with our corporate strategy which includes divesting non-core assets to provide additional non-dilutive financing. The funds will be dedicated to our ongoing Phase 3 program with cetrorelix in benign prostatic hyperplasia."

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization.
News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process a
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Involution Studios , a healthcare ... new infographic, Understanding Ebola . The goal ... easy to follow informative tool for anyone wanting to ... and prevention. , "As the news has spread in ... outbreak represents not only a healthcare crisis with global ...
(Date:10/22/2014)... Currently offering a comprehensive portfolio ... Weighing, Rice Lake, and Ohaus, Pipette.com has added ... Sartorius CPA Semi-Micro Balance is ideal for lab ... user-friendly laboratory balance. , Sartorius is a global ... balances are well known for their high performance, ...
(Date:10/22/2014)... 2014 Physicians Choice Laboratory Services ... menu, which enables healthcare providers to individualize therapeutic ... evidence-based results, healthcare providers are better able to ... while minimizing risks for adverse drug reactions and ... the FDA [1] more than 2.2 million adverse ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... On June 19 and 20 at the Drake Hotel ... real estate, legal, engineering and due diligence providers gathered ... on the small and middle markets ($10 million to ... such as "maximizing the value of your brand and ...
... Madison, Wis . - In a merging of complementary companies, ... new Vitamin D products, has acquired Proventiv Therapeutics, LLC, of ... $25 million in venture capital from Canadian and American investors. ... of Bone Care International , which was acquired last ...
... and natural gas have sparked a race to make transportation ... and gasoline containing ethanol are starting to make an impact ... has also fueled a race to find new sources for ... many modern plastics, drugs, and fuels. Behind the scenes, American ...
Cached Biology Technology:Some great insights into the current Mergers & Acquisitions Market 2Some great insights into the current Mergers & Acquisitions Market 3Some great insights into the current Mergers & Acquisitions Market 4Some great insights into the current Mergers & Acquisitions Market 5Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO 2Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO 3UW prof turns sugar into diesel fuel, chemicals 2UW prof turns sugar into diesel fuel, chemicals 3
(Date:10/15/2014)... The Ebola virus is spreading rapidly and to an ... experienced in the past and the virus shows a ... been recorded before. For this reason, the German National ... of Science and Engineering, and the Union of the ... statement on the Ebola epidemic today. , In the ...
(Date:10/15/2014)... 44th Rosenstiel Award for Distinguished Work in Biomedical Science ... mechanisms of genomic instability and its implications for the ... alumnus to win the Rosenstiel Award; the first, Rod ... is the Charles A. Janeway Professor of Pediatrics and ... investigator at the Howard Hughes Medical Institute at Boston ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... World leaders have made pitiful progress on their guarantee to ... a paper published today (Friday 15th June) in Science ... researchers have reviewed commitments made by governments to protect the ... over the past 20 years. At the World ...
... found a surprising connection between a key DNA-repair process and ... and other chronic conditions. The discovery promises to open up ... could ultimately yield novel treatments for a wide variety of ... it goes against current dogma about the role of DNA ...
... the Instituto Andaluz de Ciencias de la Tierra and other ... published in the prestigious journal Reviews of Modern Physics ... different countries has published the most comprehensive study ever done ... important contemporary issues in a field of research that is ...
Cached Biology News:A sea of broken promises 2Scientists tie DNA repair to key cell signaling network 2Spanish scientist participate in the most comprehensive study ever done on ice 2
... Thermo Savant SpeedVac Concentrators set the standard ... SC110A SpeedVac uses a combination of centrifugal force, ... a single run., SC110A comes equipped with:, , ... chemical compatibility , ...
... Savant SpeedVac™ Concentrators set the standard for sample ... SpeedVac with large chamber uses a combination of ... samples in a single run. , SC210A comes ... for long lasting chemical compatibility ...
... (for aqueous, other low volatility and noxious ... to specific applications of molecular biology and ... heat-labile samples. The RC systems can be ... and a wide selection of rotors (eliminating ...
... Jouan RC Standard Bio for vacuum ... of molecular biology and biochemistry for rapid ... RC systems can be expanded with pumps, ... selection of rotors (eliminating sample loss by ...
Biology Products: